AU2021265994B2 - Histone deacetylase inhibitors for immunomodulation in tumor microenvironment - Google Patents

Histone deacetylase inhibitors for immunomodulation in tumor microenvironment Download PDF

Info

Publication number
AU2021265994B2
AU2021265994B2 AU2021265994A AU2021265994A AU2021265994B2 AU 2021265994 B2 AU2021265994 B2 AU 2021265994B2 AU 2021265994 A AU2021265994 A AU 2021265994A AU 2021265994 A AU2021265994 A AU 2021265994A AU 2021265994 B2 AU2021265994 B2 AU 2021265994B2
Authority
AU
Australia
Prior art keywords
gntbm
gate
intensity
day
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021265994A
Other languages
English (en)
Other versions
AU2021265994A1 (en
Inventor
Ye-Su CHAO
Chia-Nan Chen
Jia-Shiong Chen
Cheng-Han Chou
Sz-Hao Chu
Yi-Hong Wu
Mu-Hsuan Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Great Novel Therapeutics Biotech & Medicals Corp
Original Assignee
Great Novel Therapeutics Biotech & Medicals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Great Novel Therapeutics Biotech & Medicals Corp filed Critical Great Novel Therapeutics Biotech & Medicals Corp
Publication of AU2021265994A1 publication Critical patent/AU2021265994A1/en
Application granted granted Critical
Publication of AU2021265994B2 publication Critical patent/AU2021265994B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2021265994A 2020-04-30 2021-04-28 Histone deacetylase inhibitors for immunomodulation in tumor microenvironment Active AU2021265994B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063018427P 2020-04-30 2020-04-30
US63/018,427 2020-04-30
PCT/CN2021/090718 WO2021219040A1 (en) 2020-04-30 2021-04-28 Histone deacetylase inhibitors for immunomodulation in tumor microenvironment

Publications (2)

Publication Number Publication Date
AU2021265994A1 AU2021265994A1 (en) 2022-12-15
AU2021265994B2 true AU2021265994B2 (en) 2024-02-29

Family

ID=78373345

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021265994A Active AU2021265994B2 (en) 2020-04-30 2021-04-28 Histone deacetylase inhibitors for immunomodulation in tumor microenvironment

Country Status (16)

Country Link
US (2) US11672788B2 (https=)
EP (1) EP4142733B1 (https=)
JP (1) JP7748392B2 (https=)
KR (1) KR20230005939A (https=)
CN (1) CN116033904A (https=)
AU (1) AU2021265994B2 (https=)
BR (1) BR112022022015A2 (https=)
ES (1) ES3051512T3 (https=)
HR (1) HRP20251279T1 (https=)
IL (1) IL297687A (https=)
MX (1) MX2022013634A (https=)
NZ (1) NZ794355A (https=)
PL (1) PL4142733T3 (https=)
TW (1) TWI849310B (https=)
WO (1) WO2021219040A1 (https=)
ZA (1) ZA202212650B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115322171B (zh) * 2022-08-30 2023-03-17 深圳微芯生物科技股份有限公司 一种trka(g667c)和flt3靶点抑制剂及其与西达本胺的组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106916101A (zh) * 2017-02-15 2017-07-04 聚缘（上海）生物科技有限公司 Nampt/hdac双靶点抑制剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
EP1738752A1 (en) * 2002-12-27 2007-01-03 Schering Aktiengesellschaft Pharmaceutical combinations comprising cis-retine acid
DK1696898T3 (en) 2003-12-02 2016-02-22 Univ Ohio State Res Found ZN2 + -CHELATING DESIGN-BASED SHORT-CHAIN FAT ACIDS AS AN UNKNOWN CLASS OF HISTONDEACETYLASE INHIBITORS
CA2702536A1 (en) * 2007-10-10 2009-04-16 Orchid Research Laboratories Limited Novel histone deacetylase inhibitors
CN103880736B (zh) * 2014-04-04 2017-05-17 深圳微芯生物科技有限责任公司 一种e构型苯甲酰胺类化合物及其药用制剂与应用
IL264068B2 (en) * 2018-01-05 2023-07-01 Great Novel Therapeutics Biotech & Medicals Corp Aggregate and pharmaceutical preparation containing an hdac inhibitor and an nsaid aggregate together with an immune checkpoint inhibitor for use in a method for removing immunosuppression in the microenvironment of a tumor or stimulating an immune system against cancer cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106916101A (zh) * 2017-02-15 2017-07-04 聚缘（上海）生物科技有限公司 Nampt/hdac双靶点抑制剂及其制备方法

Also Published As

Publication number Publication date
NZ794355A (en) 2026-02-27
AU2021265994A1 (en) 2022-12-15
KR20230005939A (ko) 2023-01-10
EP4142733A1 (en) 2023-03-08
US20230263790A1 (en) 2023-08-24
ZA202212650B (en) 2024-04-24
EP4142733B1 (en) 2025-10-01
TWI849310B (zh) 2024-07-21
HRP20251279T1 (hr) 2025-12-05
ES3051512T3 (en) 2025-12-29
MX2022013634A (es) 2022-11-16
US11672788B2 (en) 2023-06-13
IL297687A (en) 2022-12-01
US20210379032A1 (en) 2021-12-09
BR112022022015A2 (pt) 2022-12-13
TW202200557A (zh) 2022-01-01
CN116033904A (zh) 2023-04-28
JP7748392B2 (ja) 2025-10-02
US12213971B2 (en) 2025-02-04
CA3176748A1 (en) 2021-11-04
WO2021219040A1 (en) 2021-11-04
PL4142733T3 (pl) 2026-01-19
EP4142733C0 (en) 2025-10-01
JP2023524230A (ja) 2023-06-09
EP4142733A4 (en) 2023-03-08

Similar Documents

Publication Publication Date Title
US20230138480A1 (en) Compounds and uses thereof
US20250188074A1 (en) Ptpn11 inhibitors
JP6342392B2 (ja) 置換型ピラゾロン化合物及び使用方法
ES2704922T3 (es) Compuesto de triazina y uso del mismo con fines médicos
CN102459187A (zh) Janus激酶抑制化合物和方法
KR20200015888A (ko) Nav1.7 및 Nav1.8 차단제로 쓰이는 아미드 유도체
US12023333B2 (en) Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators
WO2014171464A1 (ja) Ｐａｉ－１阻害剤の新規用途
KR20240058898A (ko) 히스톤 디아세틸라제 6 및 열 충격 단백질 90의 이중 억제제
AU2021265994B2 (en) Histone deacetylase inhibitors for immunomodulation in tumor microenvironment
CA3176748C (en) Histone deacetylase inhibitors for immunomodulation in tumor microenvironment
RU2854218C1 (ru) Ингибиторы гистондеацетилазы для иммуномодуляции в микросреде опухоли
CA3086714A1 (en) Heterocycle compounds as tyro3, axl and mertk (tam) family of receptor tyrosine kinase inhibitors
HK40092030A (zh) 用於肿瘤微环境免疫调节作用的组蛋白去乙酰化酶抑制剂
EP4552695A2 (en) Tyrosine kinases inhibitors and uses thereof
BR102024021500A2 (pt) Composto, composição farmacêutica e métodos para suprimir a angiogênese, para suprimir a metástase, para suprimir a oncogênese, para modular as atividades de regulação imunológica, para tratar ou prevenir uma doença e para tratar tumores ou cânceres

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)